Bristol-Myers Squibb BMY Breyanzi — Total Revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bristol-Myers Squibb in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Bristol-Myers Squibb’s 10-Q, filed July 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bristol-Myers Squibb's breyanzi — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bristol-Myers Squibb's breyanzi — total revenues?
- Bristol-Myers Squibb (BMY) reported breyanzi — total revenues of $484M in Q2 2026.
- How has Bristol-Myers Squibb's breyanzi — total revenues changed year-over-year?
- Bristol-Myers Squibb's breyanzi — total revenues increased by 40.7% year-over-year, from $344M to $484M.
- What is the long-term trend for Bristol-Myers Squibb's breyanzi — total revenues?
- Over 4 years (2021 to 2025), Bristol-Myers Squibb's breyanzi — total revenues has grown at a 98.8% compound annual growth rate (CAGR), from $87M to $1.36B.
- What does breyanzi — total revenues mean?
- This metric represents the total global net sales generated from the commercialization of Breyanzi, a chimeric antigen receptor (CAR) T-cell therapy. It reflects the market adoption and clinical utilization of this specific cell therapy product within the oncology portfolio. Revenue growth in this segment is a key indicator of the company's success in scaling advanced, personalized medicine platforms.